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Leydig cell tumors represent 3% of testicular masses and usually occur in prepubertal boys andmen between 30 and 60 years of age.
Leydig cell tumors are benign in children but can bemalignant in 10% of adults.This case report describes a 41-year-old patient who
was diagnosed with a Leydig cell tumor that originated in his right testicle that subsequently metastasized to his liver, lungs, and
retroperitoneum.We discuss the patient’s presentation and review the radiographic findings, surgical treatment, surgical pathology,
chemotherapeutic treatment, and published literature on this rare pathology.
1. Introduction
The interstitial cells of Leydig were named after the Ger-
man anatomist Franz von Leydig who first described them.
They develop from the mesenchyme and primarily produce
testosterone in response to luteinizing hormone (LH) as well
as estrogens. Leydig cell tumors (LCTs) comprise only 1.2–
3% of testicular neoplasms; however, up to 10% of LCTs
are malignant. Malignant LCTs tend to progress at a rapid
pace with median survival of 2 years after orchiectomy [1].
Management of patients after orchiectomy is controversial, as
no standard of care exists.Wepresent a case report of a patient
who developed metastatic LCT and was managed initially
with observation and subsequently with metastasectomies
and cryoablation.
2. Case Presentation
A 41-year-old male presented with a right-sided testicular
mass. Physical examination revealed a firm, painless right-
sided testicular mass with no gynecomastia. Testicular ultra-
sound showed a 6.2 × 3.6 × 4.4 cm intratesticular lesion
suspicious for malignancy (Figure 1). Preoperative workup
including tumormarkers (𝛽-human chorionic gonadotropin,
alpha fetal protein, and lactate dehydrogenase), chest X-ray
(CXR), and Abdomen and pelvis CT was normal. He under-
went a right radical inguinal orchiectomy with pathology
showing a 5.0 cm Leydig cell tumor with negative surgical
margins (Figure 2(A)). Of note, there was moderate mitotic
activity and tumor necrosis, though no lymphovascular inva-
sion (LVI) or cellular atypia was noted. During subsequent
follow-up, he began to experience fatigue, hot-flashes, and
night sweats and was noted to have low testosterone at
180 ng/dL. FSH was 5.1 IU/L (1.4–18) and LH was 6 IU/L
(2–9). His hypogonadism was attributed to suppression of
his hypothalamic axis due to a testosterone secreting LCT.
When his testosterone level did not improve to normal levels
postoperatively, he was started on testosterone replacement
therapy (200mg IM every three weeks) which drastically
improved his symptoms.
Given the risk of malignancy, he was followed up with
CXRand serum testosterone levels every sixmonths for a year
and then yearly. Three years after orchiectomy, the patient
presented with right upper quadrant abdominal pain and
was found to have a large 15 × 15 cm right hepatic lesion
with mass effect on adjacent structures, including narrowing
of the IVC on CT (Figure 3). Since his testosterone was
1600 ng/dL at the time, he was presumed to have metastatic
LCT and subsequently an exploratory-laparotomy and right
hepatectomy with a hepaticojejunostomy with Roux-en-Y
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Figure 1: Right testicular ultrasound, showing a testicular mass with flow on Doppler.
Figure 2: (A) High magnification photomicrograph of the testicular mass showing sheets of polygonal cells with abundant eosinophilic
cytoplasm, distinct cell borders, and bland uniform nuclei with prominent nucleoli. Numerous Reinke crystals are present. (B)
Photomicrograph of metastatic Leydig cell tumor (lower right) within the liver (upper left).
reconstruction. Pathology confirmed metastatic LCT with
negative surgical margins (Figure 2(B)). After the surgery, his
testosterone level dropped to 205 ng/dL. Screening CT scans
every 3 months for a year remained negative for metastasis so
the patient resumed his testosterone replacement therapy in
order to return to his baseline energy level and quality of life.
Five years after his initial orchiectomy, his testosterone
level abruptly increased to 1287 ng/dL. A CT scan showed a
new right retrocrural mass and pulmonary node (Figure 4).
The retrocrural mass was resected and he later underwent
a video-assisted thoracoscopic surgery (VATS) of his right
lower lobe pulmonary nodule. Pathology for both procedures
redemonstrated metastatic LCT. A year later a follow-up
CT scan revealed a new right-sided retroperitoneal mass
which was treated with cryoablation (Figure 5). He remained
disease-free for a year. Seven years after orchiectomy,CT/PET
imaging noted FDG avid lesions on omental lymph nodes
and left sided pulmonary nodules as well as liver lesions
(Figure 6) with testosterone level of 6034 ng/dL. He then
underwent four cycles of cisplatin and etoposide chemother-
apy. Unfortunately, he experienced progression of disease
with increasing testosterone to 8459 ng/dL and CT showing
increasing disease burden.
3. Discussion
Leydig cell tumors (LCTs) represent 1–3% of testicularmasses
and can occur at any age but are found most commonly in
prepubertal boys and men between the ages of 30 and 60 [2].
Tumor markers (hCG, AFP, and LHD) are typically negative,
but endocrine anomalies such as elevated testosterone or
estrogen are sometimes observed [1]. In a review of 32
patients with metastatic LCT, 54% of patients had elevated
androgen levels and 50% of patients had elevated estrogen
level. According to EUAGuidelines, standard tumor markers
as well as LH, FSH, and testosterone levels should be obtained
if there is clinical suspicion of LCT. If inconclusive, estrogen,
estradiol, progesterone, and cortisol levels may be helpful.
Elevated estrogen levels, which are a result of either direct
production or indirect peripheral aromatization, can often
present as gynecomastia in 10% of patients [3]. In our patient,
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Figure 3: Abdomen and pelvis CT that shows a 16 cm mass in the
right lobe of the liver, with mass effect on the surrounding tissues,
with compression of the IVC.
Figure 4: Abdomen and pelvis CT that shows a new retrocrural
mass (arrows) and lower right pulmonary nodule (star). A previous
right hepatectomy can be observed.
we observed high serum testosterone levels with recurrence
and used it as a surrogate during follow-up in addition to
CXRs and cross-sectional imaging.
While LCTs are benign in children, they can bemalignant
in 10%of adults. Of thosewithmalignant disease, 22%present
with metastasis, whereas 19% of metastases develop within
12 months and 59% develop thereafter. In one review of 32
patients with LCTs, metastases most frequently involved the
lymph nodes (72%), lung (43%), bone (28%), and kidney
(14%) [1]. Aside from the presence of metastatic disease at
diagnosis, there are few accurate predictors of aggressive
disease. In a pathologic comparison between 25 benign and 5
malignant LCTs,Kimet al. found that patientswithmalignant
tumors tended to have larger tumors greater than 5 cm,
moderate or severe nuclear atypia, angiolymphatic invasion,
infiltrating margins, or greater than 5 mitotic features per 10
high power fields [4].
Despite a known 10% malignancy rate, there are no
standard protocols for either postorchiectomy surveillance
or more aggressive treatment such as retroperitoneal lymph
Figure 5: Abdomen and pelvis CT that shows a right-sided
retroperitoneal recurrent mass prior to cryoablation.
Figure 6: PET scan that demonstrates FDG avidity of omental
lymph nodes (stars) and retrocrural lesions (arrows and arrows
head).
node dissection (RPLND). In a recent retrospective review of
48 patients with testicular sex cord-stromal tumors including
28 patients with LCTs, Silberstein et al. found that patients
with 1 or no high risk pathologic features can be safely
observed without RPLND [5]. Conversely, it appears that
some patients with 2 or more risk factors with either clinical
stage I or clinical stage IIa disease at diagnosis seemed to ben-
efit from early RPLND. However, a subset of these patients
developed relapse regardless of early versus delayed RPLND,
indicating the progressive nature of LCTs. Given the limited
utility of chemotherapy and radiation formetastatic LCTs [6],
it appears that early RPLND may offer the possibility of a
good outcome in the setting of low nodal burden.
Though there is no standard of therapy for management
of metastatic LCTs, our limited experience has shown that
surgical resection and minimally invasive approaches such
as cryoablation may play an important role in treatment.
To our knowledge, no case reports have managed retroperi-
toneal recurrence with cryoablation. Despite having several
pathologic risk factors at diagnosis, including larger size,
tumor necrosis, and moderate mitotic activity, our patient
responded well initially to metastasectomies and cryoabla-
tion of retroperitoneal recurrence. He subsequently survived
over seven years after orchiectomy before developing widely
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progressive disease in comparison to the typical median
survival of two years after orchiectomy [1]. Additionally,
cryoablation offers a less invasive means of management
and avoids the morbidity associated with surgical resection,
especially in patients who have already undergone extensive
surgical resection. In particular, our patient had a previous
Roux-en-Y and was able to quickly resume daily activities
with minimal recovery time. However, this remains a rare
tumor and more studies are needed to evaluate the efficacy
of early RPLND versus delayed metastasectomy for the
management of metastatic LCT.
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